BioSante rises on FDA OK of male testosterone gel
This article was originally published in Scrip
Executive Summary
Shares of BioSante Pharmaceuticals ascended as high as 62% on 15 February on word that the US FDA approved Bio-T-Gel, a testosterone gel the firm has licensed to Teva's US unit, as a treatment for male hypogonadism, or low levels of testosterone, a condition that affects up to five million men over 39 years and is characterized by impotence, a lack of sex drive, decreased energy, increased body fat, muscle weakness and osteoporosis.